Qwo FDA Approval History
Last updated by Judith Stewart, BPharm on July 9, 2020.
FDA Approved: Yes (First approved July 6, 2020)
Brand name: Qwo
Generic name: collagenase clostridium histolyticum-aaes
Dosage form: for Injection
Company: Endo International plc
Treatment for: Cellulite
Qwo (collagenase clostridium histolyticum-aaes) is a combination of bacterial collagenases indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.
- Qwo is thought to enzymatically release the fibrous septae which pull the skin to the muscle fascia to cause the characteristic dimpling appearance of cellulite.
- Qwo is administered via subcutaneous injection into the treatment area of the buttocks. Each buttock can receive up to 12 injections per treatment visit. Treatment visits should be repeated every 21 days for 3 treatment visits.
- The most common adverse reactions (≥ 1%) were related to the injection site (bruising, pain, nodule, pruritus, erythema, discoloration, swelling, and warmth).
Development timeline for Qwo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.